USH1551H - Topical composition and method for reducing hair loss from human scalp - Google Patents
Topical composition and method for reducing hair loss from human scalp Download PDFInfo
- Publication number
- USH1551H USH1551H US08/132,487 US13248793A USH1551H US H1551 H USH1551 H US H1551H US 13248793 A US13248793 A US 13248793A US H1551 H USH1551 H US H1551H
- Authority
- US
- United States
- Prior art keywords
- hair
- hair loss
- oxendolone
- hairs
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000004384 Alopecia Diseases 0.000 title claims description 85
- 230000003676 hair loss Effects 0.000 title claims description 59
- 208000024963 hair loss Diseases 0.000 title claims description 43
- 210000004761 scalp Anatomy 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 6
- 230000000699 topical effect Effects 0.000 title claims description 6
- FCKLFGKATYPJPG-SSTBVEFVSA-N Oxendolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 FCKLFGKATYPJPG-SSTBVEFVSA-N 0.000 claims abstract description 33
- 229950006827 oxendolone Drugs 0.000 claims abstract description 31
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 abstract description 96
- 230000000694 effects Effects 0.000 abstract description 35
- 239000000654 additive Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 31
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 18
- 208000004631 alopecia areata Diseases 0.000 description 14
- 230000001936 parietal effect Effects 0.000 description 14
- 230000007423 decrease Effects 0.000 description 12
- 210000001061 forehead Anatomy 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 11
- 230000007803 itching Effects 0.000 description 11
- 231100000957 no side effect Toxicity 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 210000003128 head Anatomy 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 208000001840 Dandruff Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108090000854 Oxidoreductases Proteins 0.000 description 8
- 102000004316 Oxidoreductases Human genes 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- -1 etc. Natural products 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- YQACAXHKQZCEOI-UDCWSGSHSA-N (8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 YQACAXHKQZCEOI-UDCWSGSHSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003450 growing effect Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JWKSQNWLEIABLH-UHFFFAOYSA-N 1-octan-2-yloxydodecane Chemical compound CCCCCCCCCCCCOC(C)CCCCCC JWKSQNWLEIABLH-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- 208000010132 annular erythema Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- This invention relates to a hair grower which does not exhibit undesirable side-effects such as systemic hormonal activity but has an excellent hair growing effect by topical application.
- Testosterone male hormone produced in the testicles and adrenal gland is carried in the blood stream and reaches the sebaceous gland where it is converted to 5 ⁇ -dihydrotestosterone (5 ⁇ -DHT), a more potent male hormone, by the reductase present in the cells of the sebaceous gland.
- 5 ⁇ -DHT 5 ⁇ -dihydrotestosterone
- Physiological symptoms such as male pattern baldness (MPB) and seborrhea are said to develop as a result of excessive androgen stimulation due to an excessive local accumulation of testosterone.
- MPB male pattern baldness
- seborrhea seborrhea
- 5 ⁇ -DHT which is produced by reduction of testosterone in these organs by an enzyme called testosterone-5 ⁇ -reductase (briefly, reductase).
- the mechanism involved in the pathogenesis of MPB may be postulated as follows. While 5 ⁇ -DHT, which is produced in the sebaceous tissue, combines with a receptor in the sebaceous cells and acts on the nucleus to promote the growth of the cells, 5 ⁇ -DHT itself comes out of the sebaceous gland cells and is carried in the blood stream and acts on the nearby cells, i.e. hair matrix to inhibit division of the hair matrix cells and prevent growth of the hair.
- the present inventor has made extensive investigations in order to search for a substance which has no undesirable side-effect such as systemic hormonal activity, is safe, and shows an effect of inhibiting both the activity of the reductase and the binding of 5 ⁇ -DHT with the receptor protein by topical use.
- these investigations have led to the discovery that the above object can be achieved by employing oxendolone.
- the present invention was accomplished based on this discovery.
- Oxendolone which is used in this invention, is chemically known as 16 ⁇ -ethyl-17 ⁇ -hydroxy-4-estren-3-one which is available as a white or pale yellowish white, odorless powder. It is available on the market as a drug for benign prostatic hypertrophy and while it is administered intramuscularly as an aqueous suspension containing 200 mg per 2 ml (Prostetin: Trade name of Takeda Chemical Industries, Ltd., U.S. Pat. No. 3,856,829), it has never been applied as a topical agent.
- the present hair grower contains a maximum of about 2% of oxendolone in combination with a topically applicable vehicle or carrier, and if desired with further usual additives.
- the grower may contain more than about 0.001% of oxendolone and, more desirably, 0.05 to 0.2% thereof in the total preparation.
- Oxendolone is practically insoluble in water but soluble, for example, in ethanol, and, therefore, aqueous ethanol containing more than 30%, preferably 50% of ethanol may be employed as a suitable vehicle.
- Oxendolone also may be dissolved totally or partially in vegetable oils such as sesame oil, cottonseed oil, castor oil, olive oil, corn oil, peanut oil, etc., carbohydrates such as squalane, squalene, liquid paraffin, vaseline, etc., alcohols such as palmityl alcohol, hexadecyl alcohol, stearyl alcohol, oleyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, etc., fatty acids such as myristic acid, palmitic acid, stearic acid, oleic acid, etc., or silicone oils, lanoline, etc.
- vegetable oils such as sesame oil, cottonseed oil, castor oil, olive oil, corn oil, peanut oil, etc.
- carbohydrates such as squalane, squalene, liquid paraffin, vaseline, etc.
- alcohols such as palmityl alcohol, hexadecyl alcohol, stearyl alcohol, oleyl alcohol, propylene glyco
- the hair grower of the present invention may optionally contain any of those additives normally used in hair grower or hair tonics, for example germicides such as hinokitiol, surface active agents, refreshing agents such as menthol, perfumes, antioxidants, ultraviolet absorbers, dyes, moisturizers such as urea, salicylic acid, polyglyceride glycerol, etc.
- the present hair grower may be used in the form of a liquid as well as emulsions, ointments, etc., prepared by a conventional method, and can be applied several times (1 to 6 times) a day in an amount of about 0.5-10 ml, preferably 1-5 ml.
- the amount and application interval may vary with the conditions of the subject and may be used in a range of 0.1 mg to 100 mg per day, preferably 1 to 5 mg per day as oxendolone.
- the regimen of this invention prescribes rubbing 0.05 ml/cm 2 of the present drug well into the bare or downy patches of the scalp several times (1 to 6 times) a day.
- the grower is preferably used after a shampooing. It causes no particular side effect, but its use is preferably avoided in the presence of an open wound.
- the systemic acute toxicity of oxendolone is as follows:
- Rate of inhibition (%) (C-t/C) ⁇ 100
- Rate of inhibition (%) (C-t/C) ⁇ 100
- Oxendolone or 4-androsten-3-one-17 ⁇ -carboxylic acid and hardened castor oil/40 mole E0 adduct were added to 95% ethanol, and the mixture was stirred. Then, deionized water was added to the solution and mixed to obtain a transparent liquid hair grower.
- Oxendolone 0.5 g
- 2.0 g of polyoxyethylene (60 moles)/hardened castor oil 10.0 g of glycerol, 10.0 g of dipropylene glycol, 5.0 g of 1,3-butylene glycol, and 5.0 g of polyethylene glycol 1500 were dissolved by heating at 60° C.
- Cetyl isooctanoate (10.0 g), 5.0 g of squalane, 2.0 g of vaseline and 2.0 g of propyl p-oxybenzoate were dissolved by heating at 60° C. (B).
- Liquid paraffin (5.0 g), 5.5 g of cetostearyl alcohol, 5.5 g of vaseline, 3.0 g of glyceryl monostearate, 3.0 g of polyoxyethylene (20 moles) 2-octyl dodecyl ether, 0.05 g of vitamin E acetate, 0.3 g of propyl p-oxybenzoate and 0.05 g of a perfume were dissolved by heating.
- MPB represents male pattern baldness.
- FIGS. 1-6 depict clinical studies of the instant invention.
- Prominent hair loss started 2 years ago, and marked hair loss occurred during the summer to fall of 1981, causing recession of the hairline in the anterior portions of the calvarium. He was examined at the Department of Dermatology, Kyoto University Hospital for about 2 months and was instructed to apply about 2 ml of the solution 1 to the affected area once a day at bedtime. As a result, the soft hairs in the borders became harder, and objectively also, the hairline at the anterior portions definitely descended.
- Alopecia areata 29-year old female, living in Nagaokakyo City.
- the hairline in the anterior region started to recede at the age of 21. Hair loss seemed prominent in the fall to winter season. He was examined at the Department of Dermatology, Kyoto University Hospital on Feb. 9, 1982. After he applied about 2 ml the solution 1 to the anterior region once a day for about 1 month, growth of new soft hairs in the same region became prominent. No side effect was observed.
- the hair in the parietal portion was thin because of the scar of a trauma he received to the head in his childhood. For this reason he used to wear a wig.
- the hair from the frontal to parietal portions became thinner as a whole about 5 years ago, and he was examined at the Dept. of Dermatology, Kyoto University Hospital on Jul. 22, 1982. He received 2 g each of cream 1 and embrocated it into the affected area 1-2 times a day. About one month later, a decrease in hair loss and regrowth of soft hairs were observed. When he visited the hospital about 4 months later his hair appeared thicker, and he told us that hardly any hairs adhered to his wig any more. He is under follow-up, and no side effect has been seen.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/132,487 USH1551H (en) | 1982-03-20 | 1993-10-06 | Topical composition and method for reducing hair loss from human scalp |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4510382A JPS58162512A (ja) | 1982-03-20 | 1982-03-20 | 若禿及び円型脱毛の発毛剤 |
JP57-45103 | 1982-03-20 | ||
JP57-166193 | 1982-09-24 | ||
JP16619482A JPS5959607A (ja) | 1982-09-24 | 1982-09-24 | 養毛料 |
JP16619382A JPS5959606A (ja) | 1982-09-24 | 1982-09-24 | 老人性,脂漏性および「こう」糖性の脱毛症治療剤 |
JP57-166194 | 1982-09-24 | ||
US47592483A | 1983-03-16 | 1983-03-16 | |
US65987084A | 1984-10-12 | 1984-10-12 | |
US9176987A | 1987-08-27 | 1987-08-27 | |
US42652589A | 1989-10-24 | 1989-10-24 | |
US55941690A | 1990-07-25 | 1990-07-25 | |
US72986191A | 1991-07-10 | 1991-07-10 | |
US89959392A | 1992-06-18 | 1992-06-18 | |
US08/132,487 USH1551H (en) | 1982-03-20 | 1993-10-06 | Topical composition and method for reducing hair loss from human scalp |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US89959392A Continuation | 1982-03-20 | 1992-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
USH1551H true USH1551H (en) | 1996-06-04 |
Family
ID=27292115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/132,487 Abandoned USH1551H (en) | 1982-03-20 | 1993-10-06 | Topical composition and method for reducing hair loss from human scalp |
Country Status (13)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348348B1 (en) | 1998-04-07 | 2002-02-19 | The Carnegie Institution Of Washington | Human hairless gene and protein |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008038242A1 (de) | 2008-08-18 | 2010-02-25 | Elife Mendes | Mittel und Verfahren zur Behandlung des kreisrunden Haarausfalls |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856829A (en) * | 1970-01-07 | 1974-12-24 | Takeda Chemical Industries Ltd | 16{62 -hydrocarbon substituted estrane compounds |
US4272508A (en) * | 1979-03-30 | 1981-06-09 | Jurgen Tamm | Cosmetics for treatment of hair and skin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2100319C3 (de) * | 1970-01-07 | 1974-10-31 | Takeda Chemical Industries, Ltd., Osaka (Japan) | Neue Östranverbindungen, ihre Herstellung und sie enthaltende Arzneimittel |
US3917829A (en) * | 1971-11-08 | 1975-11-04 | Research Corp | Novel methods of inhibiting the activity of testosterone 5{60 -reductase |
-
1983
- 1983-03-16 GR GR70817A patent/GR77885B/el unknown
- 1983-03-17 GB GB08307346A patent/GB2122081B/en not_active Expired
- 1983-03-17 NL NL8300972A patent/NL8300972A/nl not_active Application Discontinuation
- 1983-03-18 CH CH1498/83A patent/CH657774A5/de not_active IP Right Cessation
- 1983-03-18 AU AU12573/83A patent/AU559145B2/en not_active Ceased
- 1983-03-18 BE BE0/210358A patent/BE896213A/fr not_active IP Right Cessation
- 1983-03-18 FR FR8304501A patent/FR2523440A1/fr active Granted
- 1983-03-18 DE DE19833309813 patent/DE3309813A1/de active Granted
- 1983-03-21 IT IT67316/83A patent/IT1162843B/it active
- 1983-03-21 CA CA000424076A patent/CA1222460A/en not_active Expired
-
1989
- 1989-01-11 SG SG24/89A patent/SG2489G/en unknown
- 1989-07-20 HK HK577/89A patent/HK57789A/xx unknown
-
1993
- 1993-10-06 US US08/132,487 patent/USH1551H/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856829A (en) * | 1970-01-07 | 1974-12-24 | Takeda Chemical Industries Ltd | 16{62 -hydrocarbon substituted estrane compounds |
US4272508A (en) * | 1979-03-30 | 1981-06-09 | Jurgen Tamm | Cosmetics for treatment of hair and skin |
Non-Patent Citations (3)
Title |
---|
Chemical Abstracts (1973) vol. 79 Par. 73,914s. * |
Federal Register, 21CFR Part 310 Tues Jan. 15, 1985 pp. 2190 2198. * |
Federal Register, 21CFR Part 310 Tues Jan. 15, 1985 pp. 2190-2198. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348348B1 (en) | 1998-04-07 | 2002-02-19 | The Carnegie Institution Of Washington | Human hairless gene and protein |
US20030027300A1 (en) * | 1998-04-07 | 2003-02-06 | Carnegie Institution Of Washington | Human hairless gene and protein |
US7416731B2 (en) | 1998-04-07 | 2008-08-26 | The Carnegie Institution Of Washington | Human hairless antibodies |
Also Published As
Publication number | Publication date |
---|---|
GR77885B (enrdf_load_stackoverflow) | 1984-09-25 |
DE3309813A1 (de) | 1983-10-13 |
IT8367316A0 (it) | 1983-03-21 |
GB2122081A (en) | 1984-01-11 |
AU559145B2 (en) | 1987-02-26 |
CA1222460A (en) | 1987-06-02 |
BE896213A (fr) | 1983-09-19 |
FR2523440A1 (fr) | 1983-09-23 |
HK57789A (en) | 1989-07-28 |
FR2523440B1 (enrdf_load_stackoverflow) | 1984-12-14 |
DE3309813C2 (enrdf_load_stackoverflow) | 1992-07-02 |
NL8300972A (nl) | 1983-10-17 |
SG2489G (en) | 1989-06-02 |
GB2122081B (en) | 1986-04-03 |
AU1257383A (en) | 1983-09-22 |
GB8307346D0 (en) | 1983-04-27 |
IT1162843B (it) | 1987-04-01 |
CH657774A5 (de) | 1986-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2244690B1 (en) | Topical compositions for treating inflammatory disorders, diseases and conditions | |
JP3049593B2 (ja) | 育毛・養毛剤 | |
US10869822B2 (en) | Compositions for treatment of dermatological diseases and conditions and methods of use thereof | |
CN102724951A (zh) | 用于刺激毛发生长的组合物和方法 | |
DE3685696T2 (de) | Melatoninhaltige mittel sowie deren verwendungen. | |
CA2324077C (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
USH1551H (en) | Topical composition and method for reducing hair loss from human scalp | |
JPH11269043A (ja) | 頭皮頭髪用化粧料 | |
JPS6127914A (ja) | 化粧料 | |
US5609858A (en) | Method for treatment of androgenic alopecia | |
PT659080E (pt) | Metodo e composicao cosmeticos para a queda de cabelo | |
US4272508A (en) | Cosmetics for treatment of hair and skin | |
JPH11269042A (ja) | 頭皮頭髪用化粧料 | |
JPH0112725B2 (enrdf_load_stackoverflow) | ||
JPS6028926A (ja) | 皮膚外用剤 | |
JPS60215608A (ja) | 養毛料 | |
CN119161241A (zh) | 毛发生长的刺激 | |
JPH0577647B2 (enrdf_load_stackoverflow) | ||
JPH07149614A (ja) | 養毛料 | |
JPS5988409A (ja) | 養毛料 | |
JPH0834720A (ja) | 皮膚外用剤 | |
JPH0441122B2 (enrdf_load_stackoverflow) | ||
JPH0519524B2 (enrdf_load_stackoverflow) | ||
JPS6054310A (ja) | 化粧料 | |
HK1150155B (en) | Topical compositions for treating inflammatory disorders, diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |